explore -WSS

explore

author：fashion 2025-09-28 17:06:54 - browse：42

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Doulas covered by Medicaid under New York's new plan

WSS

Medicare must police algorithms in Medicare Advantage, Dems say

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Risky weight loss products often used by teens globally, per study

Explaining an after

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

focus

explore

entertainment

Drug repurposing or repositioning? The language matters

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Guidelines to prevent youth baseball injuries need more muscle

Caregivers of transplant patients call for more support, training

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: live from JPM 2024

Guidelines to prevent youth baseball injuries need more muscle

New Medicare drug pricing powers could soon be upended in court

New air purifier tech could be key to improving indoor air quality

The health care issue Democrats can’t solve: hospital reform

focus

Lung cancer screening guidelines updated for cigarette smokers

HHS names first

Readout LOUD podcast: ESMO highlights & Roivant's big deal

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

As JPM 2024 winds down, some health tech firms project optimism

Explaining an after

Wikipedia

focus

focus

leisure time